XTX-202

N/A

Report date: 2023/12/29 16:53:22

Base Information

Drug NameXTX-202
Drug Alias Namea tumor-activated, beta-gamma biased, engineered IL-2XTX-202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsSolid tumoursCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXilio Development IncXilio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesXilio Therapeutics IncXilio Development Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Renal CellMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A